Hence, these genes might serve as molecular targets to restrict oncogenic (i.e. ATIC, BZW2) and lipogenic (i.e. CD36, PPARγ), but promote tumor suppressive (i.e. TAGLN2) activity to treat human HCC. This evidence concerns the gene PPARG and neoplasm.